Updated on 30 April 2025
prof.
About
Main topic: Delivery of nucleic acids, proteins, and drugs into cells and tissues using cell electroporation
Main applications:
Development of antitumor therapy based on irreversible electroporation and electrochemotherapy (anticancer drugs or calcium electroporation), combination with radiotherapy.
Investigation of delivery of nucleic acids, proteins and other molecules to cells and tissues for genetic modification and vaccination.
Controlled inactivation and genetic modification of microorganisms.
Investigation and application of irreversible cell electroporation for ablation of abberant zones in cardiac tissue to treat atrial fibrillation.
Development and commercialization of electroporation equipment and tools. To this end a spinoff company Amber Charge was founded: https://ambercharge.eu
Topic
- Cluster Health (CL1): HORIZON-HLTH-2025-03-DISEASE-02-two-stage: Advancing innovative interventions for mental, behavioural and neurodevelopmental disorders
- Cluster Food (CL6): HORIZON-CL6-2025-02-FARM2FORK-12 Nutrition and Mental Health
- Cluster Health (CL1): HORIZON-HLTH-2025-03-ENVHLTH-02-two-stage: Advancing knowledge on the impacts of micro- and nanoplastics on human health
Type
- Partner seeks Consortium/Coordinator
Similar opportunities
Project cooperation
Nutrition and Mental health projects
- Partner seeks Consortium/Coordinator
- Cluster Food (CL6): HORIZON-CL6-2025-02-FARM2FORK-12 Nutrition and Mental Health
Egidijus Šimoliūnas
Researcher at Layer Pharma
Vilnius, Lithuania
Project cooperation
Partnering for Health and Sustainability: SABİOTEK at Yıldız Technical University
- Cluster Food (CL6): HORIZON-CL6-2025-02-FARM2FORK-12 Nutrition and Mental Health
- Cluster Health (CL1): HORIZON-HLTH-2025-01-DISEASE-04: Leveraging artificial intelligence for pandemic preparedness and response
- Cluster Health (CL1): HORIZON-HLTH-2025-03-ENVHLTH-02-two-stage: Advancing knowledge on the impacts of micro- and nanoplastics on human health
- Cluster Health (CL1): HORIZON-HLTH-2025-01-CARE-01: End user-driven application of Generative Artificial Intelligence models in healthcare (GenAI4EU)
- Cluster Health (CL1): HORIZON-HLTH-2025-03-ENVHLTH-01-two-stage: The impact of pollution on the development and progression of brain diseases and disorders
- Cluster Health (CL1): HORIZON-HLTH-2025-03-STAYHLTH-01-two-stage: Improving the quality of life of persons with intellectual disabilities and their families
- Cluster Health (CL1): HORIZON-HLTH-2025-03-DISEASE-02-two-stage: Advancing innovative interventions for mental, behavioural and neurodevelopmental disorders
- Cancer Mission: HORIZON-MISS-2025-02-CANCER-02: Understanding the effects of environmental exposure on the risk of paediatric, adolescent and young adult cancers
- Cluster Health (CL1): HORIZON-HLTH-2025-01-TOOL-03: Leveraging multimodal data to advance Generative Artificial Intelligence applicability in biomedical research (GenAI4EU)
Cem Ustundag
Professor at Yildiz Technical University
istanbul, Türkiye
Project cooperation
Expert Systems in the field of Health
- Partner seeks Consortium/Coordinator
- Cluster Food (CL6): HORIZON-CL6-2025-02-FARM2FORK-12 Nutrition and Mental Health
- Cluster Health (CL1): HORIZON-HLTH-2025-01-DISEASE-04: Leveraging artificial intelligence for pandemic preparedness and response
- Cluster Health (CL1): HORIZON-HLTH-2025-03-ENVHLTH-02-two-stage: Advancing knowledge on the impacts of micro- and nanoplastics on human health
- Cluster Health (CL1): HORIZON-HLTH-2025-01-CARE-01: End user-driven application of Generative Artificial Intelligence models in healthcare (GenAI4EU)
- Cluster Health (CL1): HORIZON-HLTH-2025-03-STAYHLTH-01-two-stage: Improving the quality of life of persons with intellectual disabilities and their families
- Cluster Health (CL1): HORIZON-HLTH-2025-03-DISEASE-02-two-stage: Advancing innovative interventions for mental, behavioural and neurodevelopmental disorders
- Cluster Health (CL1): HORIZON-HLTH-2025-01-TOOL-03: Leveraging multimodal data to advance Generative Artificial Intelligence applicability in biomedical research (GenAI4EU)
George Nikolaidis
CEO at Ergobyte Informatics S.A.
Thessaloniki, Greece